Gcobisa Ndlangalavu

Gcobisa Ndlangalavu

Auto-generated profile, based on publicly available information

Gcobisa Ndlangalavu

Department of Science and Innovation-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Respiration
Verified
Journal Article
Open access
PDF file
SAShima M. Abdulgader
Shima M. Abdulgader
AOAnna Okunola
Anna Okunola
GNGcobisa Ndlangalavu
Gcobisa Ndlangalavu
BRByron W.P. Reeve
Byron W.P. Reeve
BABrian W. Allwood
Brian W. Allwood
GTGrant Theron
Grant Theron
New tuberculosis (TB) diagnostics are at a crossroads: their development, evaluation, and implementation is severely damaged by resource diversion due to COVID-19. Yet several technologies, especially those with potential for non-invasive non-sputum-based testing, hold promise for efficiently triaging and rapidly confirming TB near point-of-care. Such tests are, however, progressing through the pipeline slowly and will take years to reach patients and health workers. Compellingly, such tests will create new opportunities for difficult-to-diagnose populations, including primary care attendees (all-comers in high burden settings irrespective of reason for presentation) and community members (with early stage disease or risk factors like HIV), many of whom cannot easily produce sputum. Critically, all upcoming technologies have limitations that implementers and health workers need to be cognizant of to ensure optimal deployment without undermining confidence in a technology that still offers improvements over the status quo. In this state-of-the-art review, we critically appraise such technologies for active pulmonary TB diagnosis. We highlight strengths, limitations, outstanding research questions, and how current and future tests could be used in the presence of these limitations and uncertainties. Among triage tests, CRP (for which commercial near point-of-care devices exist) and computer-aided detection software with digital chest X-ray hold promise, together with late-stage blood-based assays that detect host and/or microbial biomarkers; however, aside from a handful of prototypes, the latter category has a shortage of promising late-stage alternatives. Furthermore, positive results from new triage tests may have utility in people without TB; however, their utility for informing diagnostic pathways for other diseases is under-researched (most sick people tested for TB do not have TB). For confirmatory tests, few true point-of-care options will be available soon; however, combining novel approaches like tongue swabs with established tests like Ultra have short-term promise but first require optimizations to specimen collection and processing procedures. Concerningly, no technologies yet have compelling evidence of meeting the World Health Organization optimal target product profile performance criteria, especially for important operational criteria crucial for field deployment. This is alarming as the target product profile criteria are themselves almost a decade old and require urgent revision, especially to cater for technologies made prominent by the COVID-19 diagnostic response (e.g., at-home testing and connectivity solutions). Throughout the review, we underscore the importance of how target populations and settings affect test performance and how the criteria by which these tests should be judged vary by use case, including in active case finding. Lastly, we advocate for health workers and researchers to themselves be vocal proponents of the uptake of both new tests and those – already available tests that remain suboptimally utilized.

18 July 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
LRLoren Rockman
Loren Rockman
SAShima M Abdulgader
Shima M Abdulgader
SMStephanie Minnies
Stephanie Minnies
ZPZaida Palmer
Zaida Palmer
CNCharissa Naidoo
Charissa Naidoo
GTGrant Theron
Grant Theron
Background: Oral samples show promise for tuberculosis (TB) diagnosis, but data from different sample types and sputum-scarce individuals remain limited. Methods: We evaluated Xpert MTB/RIF Ultra (Ultra) in symptomatic clinic attendees (cohort A, n = 891) and people initiating antiretroviral therapy without symptom screening (cohort B, n = 258). In cohort A, we collected oral washes (OWs) and, separately, tongue swabs (flocked or foam with heat). In cohort B, we collected OWs, 3 flocked tongue swabs (1 heated, 2 pooled), and, separately, buccal swabs and periodontal brushes. Sputum induction was offered, and different culture methods were applied to a subset of cohort B tongue swabs. Results: In cohort A, Ultra sensitivity was 80% (95% confidence interval [CI], 56%–94%) for OWs, 59% (95% CI, 53%–65%) for flocked swabs, and 65% (95% CI, 58%–72%) for foam swabs, with high specificity. Foam swabs detected more people with Ultra sputum semi-quantitation categories of low or less than flocked swabs (53% [95% CI, 41%–64%] vs 37% [95% CI, 29%–46%]). In cohort B, OWs and single heated swabs had sensitivities of 71% (95% CI, 42%–92%) and 64% (95% CI, 35%–87%), respectively. Pooled tongue swabs, buccal swabs, and brushes had lower sensitivity. MGIT960 showed the highest sensitivity (64% [95% CI, 35%–87%]) among culture methods. Oral sampling identified TB in sputum-scarce people: 25% (7/28) positive by flocked or foam swabs (cohort A); 18% (10/56) were OW and 23% (13/56) single swab positive (cohort B). In cohort B, this could double Ultra positivity if induction were unavailable. Conclusions: Ultra on OWs or foam swabs offers higher sensitivity than other oral methods and effectively detects TB in sputum-scarce individuals.

14 May 2026 in eClinicalMedicine
Verified
Journal Article
Open access
WNWelile V. Nwamba
Welile V. Nwamba
AOAnna Okunola
Anna Okunola
RCRebecca Crowder
Rebecca Crowder
DCDevasahayam J. Christopher
Devasahayam J. Christopher
WWWilliam Worodria
William Worodria
GTGrant Theron
Grant Theron
Tuberculosis (TB) testing often excludes people who cannot expectorate sputum. Non-sputum tests are a priority; however, there are limited data on the frequency and characteristics of sputum scarcity, which will influence the impact of non-sputum tests. We analysed adults with presumptive pulmonary TB recruited between February 2018 and February 2024 from a multi-country study (South Africa, Uganda, India, The Philippines; Cohort A, n = 2224), a South African cohort (Cohort B, n = 2179), and a South African cohort of people living with HIV (PLHIV) initiating antiretroviral therapy (ART) without syndromic selection (Cohort C, n = 297). Participants provided sputum for Xpert MTB/RIF Ultra (Ultra) and MGIT960 culture. Individuals unable to spontaneously produce sputum (non-salivary, ≥1 ml) underwent induction. We performed multivariable regression analysis and present adjusted ORs from LASSO to describe the relationship of variables with sputum scarcity. Separate sub-analysis was conducted for variables with >10% missing data. Overall, 13% (618/4700) people had sputum scarcity. Female sex [adjusted odds ratio [(aOR) 1.58 (95% confidence interval (CI) 1.31, 1.91)], and culture-negativity [1.45 (1.02, 2.08)] were positively associated with sputum scarcity. In Cohort A and B, country was also positively associated with sputum scarcity: India [1.43 (1.07, 1.91) and The Philippines [7.16 (5.34, 9.61] relative to South Africa. Smoking [0.61 (0.43, 0.88)], TB symptoms: cough [0.17 (0.13, 025)] and night sweats [0.71 (0.58, 0.86)] were negatively associated with sputum scarcity as well as previous TB [0.63 (0.47, 0.85)]. In people with TB, the only additional factor associated with sputum scarcity was, among PLHIV, being on ART [3.70 (1.19, 11.46)] were positively associated with sputum scarcity. Ultra sensitivity did not differ between induced and expectorated sputum [84% (64, 95) vs. 89% (84, 93); p = 0.218]. People with sputum scarcity are more likely to be female, do not smoke, have few symptoms and test culture-negative. Sputum scarcity also shows geographic variation. Among people with TB, those on ART are more likely to be sputum-scare. Sputum induction did not compromise Ultra sensitivity compared to expectorated sputum. These findings highlight people who may benefit most from non-sputum tests and the importance of such tests in people with milder disease. R2D2 TB Network and EDCTP programmes supported by the EU.